In 2012, tofacitinib, the pan-JAK inhibitor that primarily inhibits JAK1 and JAK3, and to a lesser extent JAK2, followed as the second FDA-approved jakinib, and the first jakinib approved for the treatment of RA (28) (Table 1). Here, JAK2 is linked to rheumatoid arthritis.